Is ensifentrine-Ohtuvayre officially on sale in China?

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre has not been officially launched in mainland China. Although there is news that the drug may be available through special channels in some administrative districts, it is still not available through hospital pharmacies or retail channels in most areas. The approval, marketing registration and medical insurance coverage of imported drugs are still in the evaluation stage, which means that it will be difficult for ordinary domestic patients with chronic obstructive pulmonary disease (COPD) to use the drug in the short term. In clinical practice, we still mainly rely on long-acting bronchodilators, inhaled corticosteroids and their compound regimens to control COPD symptoms.

In overseas markets, exefantine has been approved for use in patients with moderate to severe COPD, demonstrating its potential in improving lung function, relieving shortness of breath and reducing acute exacerbations. Exefentine inhalation is designed for multiple daily inhalations, with the dosage adjusted according to the patient's condition and physician guidance, to facilitate long-term management of COPD in a home environment. The inhaled form allows the drug to act directly on the airways, achieving high local concentrations and reducing the risk of systemic side effects, thus improving long-term compliance and treatment experience.

Overall, exefantine is still an innovative drug in the country and its market accessibility is limited. Patients and doctors need to pay close attention to official drug registration progress and clinical trial information, and at the same time develop reasonable management strategies based on existing treatment options. In the future, with the accumulation of clinical data and the advancement of the approval process, Ensefentin is expected to be officially launched in China and become a new choice for the treatment of COPD, providing patients with a more scientific, personalized and modern disease management plan, while improving symptoms, reducing acute exacerbations and improving quality of life.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html